IMR Press / RCM / Volume 23 / Issue 11 / DOI: 10.31083/j.rcm2311378
Open Access Review
Pulmonary Arterial Hypertension: Emerging Principles of Precision Medicine across Basic Science to Clinical Practice
Show Less
1 Center for Pulmonary Vascular Biology and Medicine and Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute; Division of Cardiology; Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
*Correspondence: (Stephen Y. Chan)
Academic Editor: Harald Kaemmerer
Rev. Cardiovasc. Med. 2022, 23(11), 378;
Submitted: 16 June 2022 | Revised: 20 August 2022 | Accepted: 9 September 2022 | Published: 9 November 2022
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Pulmonary arterial hypertension (PAH) is an enigmatic and deadly vascular disease with no known cure. Recent years have seen rapid advances in our understanding of the molecular underpinnings of PAH, with an expanding knowledge of the molecular, cellular, and systems-level drivers of disease that are being translated into novel therapeutic modalities. Simultaneous advances in clinical technology have led to a growing list of tools with potential application to diagnosis and phenotyping. Guided by fundamental biology, these developments hold the potential to usher in a new era of personalized medicine in PAH with broad implications for patient management and great promise for improved outcomes.

pulmonary hypertension
disease mechanism
systems biology
translational biology
precision medicine
T32 HL129964/NIH
R01 HL124021/NIH
R01 HL 122596/NIH
Fig. 1.
Back to top